BioCryst Pharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BCRX research report →
About the company
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on discovering and developing novel, orally administered, small-molecule therapeutics. The company currently markets two key products: Peramivir injection: An intravenous neuraminidase inhibitor, sold under the brand names RAPIVAB, RAPIACTA, and PERAMIFLU, used for the treatment of acute uncomplicated influenza.
- CEO
- Charles K. Gayer
- IPO
- 1994
- Employees
- 580
- HQ
- Durham, NC, US
Price Chart
- Market Cap
- $1.83B
- P/E
- -4.60
- P/S
- 2.06
- P/B
- -3.81
- EV/EBITDA
- -6.73
- Div Yield
- 0.00%
- Gross Margin
- 18.89%
- Op Margin
- -43.11%
- Net Margin
- -51.71%
- ROE
- 123.57%
- ROIC
- -121.96%
- Revenue
- $874.84M · 94.10%
- Net Income
- $263.86M · 396.87%
- EPS
- $1.26 · 393.02%
- Op Income
- $340.99M
- FCF YoY
- 716.08%
- 52W High
- $10.47
- 52W Low
- $6.00
- 50D MA
- $8.95
- 200D MA
- $7.92
- Beta
- 0.56
- Avg Volume
- 5.14M
Get TickerSpark's AI analysis on BCRX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 29, 26 | Milne Jill C. | other | 1,262 |
| May 29, 26 | Stonehouse Jon P | other | 631 |
| May 29, 26 | McKee Amy E | other | 631 |
| May 29, 26 | MILANO VINCENT | other | 1,122 |
| May 29, 26 | Frank Steven | other | 1,262 |
| May 18, 26 | McKee Amy E | sell | 11,180 |
| May 13, 26 | Barnes Alane P | other | 62,500 |
| May 13, 26 | Barnes Alane P | sell | 62,500 |
| May 13, 26 | Barnes Alane P | other | 62,500 |
| Apr 6, 26 | Menon Sandeep | other | 441,350 |
Our BCRX coverage
Recent articles, reports, and earnings notes.
Want a deeper read on BCRX?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Similar companies
Peers in the same neighborhood.